the staff of the Ridgewood blog
Ridgewood NJ, according to Johns Hopkins Center for Health Security , ELI LILLY A recent study published in the New England Journal of Medicine last week reported that convalescent plasma derived monoclonal antibody treatment (LY-CoV555), developed by Eli Lilly, showed clinical benefit in patients. The study found that patients experienced decreased viral loads and severity, and had no serious adverse effects in outpatients. The phase II trial involved outpatients that had mild to moderate COVID-19. A total of 452 patients participated, receiving either low, medium or high concentration of the antibody, or placebo. Researchers measured the change in viral load after 11 days of treatment, and the study has reported on interim findings. Patients receiving the medium dose (2800 mg) had about a 3 fold reduction in viral load. Differences among placebo and treatment groups were non-significant and smaller for both the low and the high dosage categories. However, patients receiving any antibody dose had lower symptom severity as well as lower hospitalization rates than placebo. Additionally, the percentage of adverse events was similar across treatment and placebo groups.
Continue reading ELI LILLY monoclonal antibody treatment for COVID Shows Promise
